دورية أكاديمية
أعرض في EDS

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

التفاصيل البيبلوغرافية
العنوان: Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.
المؤلفون: De Bernardi B; Department of Paediatric Haematology and Oncology, Giannina Gaslini Children's Hospital, Genova, Italy. brunodebernardi@ospedale-gaslini.ge.it, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda AF, Pearson AD, De Kraker J, Ambros PF, de Rycke Y, Conte M, Bruzzi P, Michon J
مؤلفون مشاركون: SIOP Europe Neuroblastoma Group
المصدر: British journal of cancer [Br J Cancer] 2008 Oct 07; Vol. 99 (7), pp. 1027-33. Date of Electronic Publication: 2008 Sep 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Neuroblastoma/*surgery, Disease Progression ; Disease-Free Survival ; Europe ; Female ; Genes, myc ; Humans ; Infant ; Infant, Newborn ; Male ; Neuroblastoma/genetics ; Prognosis ; Recurrence ; Survival Rate
مستخلص: Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1-2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6-97) and 98.9% (95% CI: 97.7-100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS 82.8%, 95% CI: 76.2-89.5; OS 93.2%, 95% CI: 88.7-97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2 patients with MYCNA were at greater risk of relapse.
References: Ann Oncol. 2002 Jun;13(6):956-64. (PMID: 12123342)
J Clin Oncol. 2005 Dec 1;23(34):8819-27. (PMID: 16314642)
Cancer Lett. 2005 Oct 18;228(1-2):283-99. (PMID: 15975710)
Eur J Pediatr Surg. 2002 Dec;12(6):402-9. (PMID: 12548494)
Am J Clin Oncol. 1992 Aug;15(4):295-303. (PMID: 1514525)
Cancer. 2001 Nov 1;92(9):2451-61. (PMID: 11745303)
Cancer Res. 1985 Jun;45(6):2843-8. (PMID: 3986811)
Cancer. 1999 Jul 15;86(2):364-72. (PMID: 10421273)
J Clin Oncol. 1993 Aug;11(8):1466-77. (PMID: 8336186)
J Clin Oncol. 1995 Apr;13(4):884-93. (PMID: 7707115)
J Clin Oncol. 2003 Apr 15;21(8):1592-601. (PMID: 12697885)
Med Pediatr Oncol. 1984;12(4):260-3. (PMID: 6749057)
Pediatr Blood Cancer. 2007 May;48(5):504-9. (PMID: 16732582)
J Clin Oncol. 1996 Sep;14(9):2504-10. (PMID: 8823329)
J Clin Oncol. 2003 Jun 1;21(11):2077-84. (PMID: 12775732)
Arch Dis Child. 1982 Jun;57(6):438-42. (PMID: 7092308)
J Clin Oncol. 2006 Feb 1;24(4):695-9. (PMID: 16446343)
Radiology. 2002 Apr;223(1):168-75. (PMID: 11930063)
J Pediatr Hematol Oncol. 2000 May-Jun;22(3):197-205. (PMID: 10864050)
Cancer. 1986 Mar 15;57(6):1230-4. (PMID: 3002599)
J Clin Oncol. 2005 Nov 20;23(33):8483-9. (PMID: 16293878)
Tumori. 1983 Aug 31;69(4):327-9. (PMID: 6623655)
J Clin Oncol. 1989 Feb;7(2):236-44. (PMID: 2915240)
J Clin Oncol. 1997 Mar;15(3):1171-82. (PMID: 9060561)
Cancer. 1992 Sep 15;70(6):1625-33. (PMID: 1516016)
J Clin Oncol. 2000 Jan;18(1):18-26. (PMID: 10623689)
J Clin Oncol. 1996 Jul;14(7):2174-80. (PMID: 8683252)
تواريخ الأحداث: Date Created: 20080904 Date Completed: 20081016 Latest Revision: 20211020
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC2567095
DOI: 10.1038/sj.bjc.6604640
PMID: 18766186
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/sj.bjc.6604640